Albendazole therapy for neurocysticercosis: A prospective double-blind trial comparing 7 versus 14 days of treatment
Albendazole therapy for neurocysticercosis: A prospective double-blind trial comparing 7 versus 14 days of treatment
复制标题
DOI：
10.1212/wnl.48.5.1421
复制
发表时间：
1997-05-01
期刊：
影响因子：
9.9
通讯作者：
Rocca, U
中科院分区：
文献类型：
--
作者：
Garcia, HH;Gilman, RH;Rocca, U
目的：比较阿苯达唑两种方案治疗脑囊虫病的疗效。设计：随机双盲临床试验。背景：秘鲁利马神经科病房收治的患者。患者：经CT和Western印迹（免疫印迹）证实的活动性脑囊虫病成人患者。干预：阿苯达唑治疗1周（n=25）与2周（n=25）。测量：CT上囊肿数量减少。结果：阿苯达唑组有效率为78%，治疗3个月后两组比较无显著性差异。只有38%的患者完全治愈。超过20个囊肿的患者对治疗的反应较差。大多数患者的临床病程和EEG演变得到改善。38%的患者出现了副作用，主要是轻度、短暂的胃肠道症状。治疗还与神经系统症状加重相关。两名患者在治疗后的第一年死亡，都是因为脑室-腹膜分流的聚集性感染。一年的随访CT显示，10例患者中有3例在治疗后3个月治愈。结论：阿苯达唑治疗时间延长超过7天对患者无任何益处。
Objective: To compare the effectiveness of two regimens of albendazole therapy for neurocysticercosis. Design: Randomized, double-blind clinical trial. Settings: Patients admitted to neurologic wards in Lima, Peru. Patients: Adult patients with active neurocysticercosis demonstrated by CT and Western blot (immunoblot). Intervention: One week (n=25) versus 2 weeks (n=25) of albendazole therapy. Measurements: Decrease in the number of cysts on CT. Results: Effectiveness of albendazole was 78%, with no difference between the groups when compared 3 months after therapy. Complete cure was obtained in only 38% of patients. Patients with more than 20 cysts had poorer responses to therapy. The clinical course and EEG evolution improved in most patients. Side effects were present in 38% of patients, mainly mild, transient gastrointestinal symptoms. Therapy was also associated with exacerbation of neurologic symptoms. Two patients died in the first year after therapy, both because of aggregated infections of ventnicle-peritoneal shunts. One-year follow-up CT showed lesions in three of 10 patients presumed to be cured 3 months after therapy. Conclusions: Extension of albendazole therapy for more than 7 days adds no benefits for the patients.